Unknown

Dataset Information

Acylation-stimulating protein and heart failure progression in arrhythmogenic right ventricular cardiomyopathy.


ABSTRACT:

Aims

Our previous studies suggested that the complement system was critical in the prognosis of arrhythmogenic right ventricular cardiomyopathy (ARVC). The acylation-stimulating protein (ASP), generated through the alternate complement pathway, was reported to regulate lipogenesis and triglyceride storage. This study aimed to investigate the role of ASP in predicting adverse cardiac events in an ARVC cohort.

Methods and results

We enrolled 111 ARVC patients and 106 healthy volunteers, and measured their plasma ASP levels using enzyme-linked immunosorbent assays. Plasma ASP levels were significantly higher in the ARVC patients than in the healthy controls (2325.22 ± 20.08 vs. 2189.75 ± 15.55, P < 0.001), with a similar trend observed in the myocardial explant assay. Spearman

SUBMITTER: Ren J 

PROVIDER: S-EPMC9871714 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature